

STATE OF MICHIGAN DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS LANSING

SHELLY EDGERTON DIRECTOR

July 9, 2018

FINAL DETERMINATION OF THE DEPARTMENT

In accordance with the Michigan Medical Marihuana Act, Initiated Law 1 of 2008, MCL 333.26421, *et seq.* (MMMA), and the associated Michigan Administrative Rules, R 333.101 *et seq.*, a Petition was filed with the Department of Licensing and Regulatory Affairs (Department) to consider adding Arthritis to the list of debilitating medical conditions under MCL 333.26423(b) and pursuant to R 333.131 and R 333.133.

The Medical Marihuana Review Panel (Panel) held a public hearing on April 27, 2018, to hear public comment on the Petition. In addition, public comment was accepted for five business days. In accordance with R 333.131(5), a majority of the Panel of those present at a meeting shall concur with the recommendation in order to be considered an official recommendation of the Panel.

On May 4, 2018, the Panel met to review and make a recommendation to the Department regarding whether the Petition should be approved or denied. After discussion, the Panel voted 4 to 2 to recommend that the Petition for Arthritis be approved pursuant to MCL 333.26426(k). As required by MCL 333.26425(a), the official recommendation of the Panel now comes to the Department for final action. The Department shall approve or deny a Petition within 180 days of the submission of the Petition.

By the authority granted to the Department pursuant to the MMMA and associated Administrative Rules, and in consideration of the recommendation concurred on by a majority of the Panel, the final determination is that the Petition for Arthritis is approved.

Shilly Edgestr

Shelly Edgerton, Director Department of Licensing and Regulatory Affairs



STATE OF MICHIGAN DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS LANSING

SHELLY EDGERTON DIRECTOR

July 9, 2018

FINAL DETERMINATION OF THE DEPARTMENT

In accordance with the Michigan Medical Marihuana Act, Initiated Law 1 of 2008, MCL 333.26421, *et seq.* (MMMA), and the associated Michigan Administrative Rules, R 333.101 *et seq.*, a Petition was filed with the Department of Licensing and Regulatory Affairs (Department) to consider adding Autism to the list of debilitating medical conditions under MCL 333.26423(b) and pursuant to R 333.131 and R 333.133.

The Medical Marihuana Review Panel (Panel) held a public hearing on April 27, 2018, to hear public comment on the Petition. In addition, public comment was accepted for five business days. In accordance with R 333.131(5), a majority of the Panel of those present at a meeting shall concur with the recommendation in order to be considered an official recommendation of the Panel.

On May 4, 2018, the Panel met to review and make a recommendation to the Department regarding whether the Petition should be approved or denied. After discussion, the Panel voted 5 to 1 to recommend that the Petition for Autism be approved pursuant to MCL 333.26426(k). As required by MCL 333.26425(a), the official recommendation of the Panel now comes to the Department for final action. The Department shall approve or deny a Petition within 180 days of the submission of the Petition.

By the authority granted to the Department pursuant to the MMMA and associated Administrative Rules, and in consideration of the recommendation concurred on by a majority of the Panel, the final determination is that the Petition for Autism is approved.

helle Edgish

Shelly Edgerton, Director Department of Licensing and Regulatory Affairs



STATE OF MICHIGAN DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS LANSING

SHELLY EDGERTON DIRECTOR

July 9, 2018

FINAL DETERMINATION OF THE DEPARTMENT

In accordance with the Michigan Medical Marihuana Act, Initiated Law 1 of 2008, MCL 333.26421, *et seq.* (MMMA), and the associated Michigan Administrative Rules, R 333.101 *et seq.*, a Petition was filed with the Department of Licensing and Regulatory Affairs (Department) to consider adding Chronic Pain to the list of debilitating medical conditions under MCL 333.26423(b) and pursuant to R 333.131 and R 333.133.

The Medical Marihuana Review Panel (Panel) held a public hearing on April 27, 2018, to hear public comment on the Petition. In addition, public comment was accepted for five business days. In accordance with R 333.131(5), a majority of the Panel of those present at a meeting shall concur with the recommendation in order to be considered an official recommendation of the Panel.

On May 4, 2018, the Panel met to review and make a recommendation to the Department regarding whether the Petition should be approved or denied. After discussion, the Panel voted 5 to 1 to recommend that the Petition for Chronic Pain be approved pursuant to MCL 333.26426(k). As required by MCL 333.26425(a), the official recommendation of the Panel now comes to the Department for final action. The Department shall approve or deny a Petition within 180 days of the submission of the Petition.

By the authority granted to the Department pursuant to the MMMA and associated Administrative Rules, and in consideration of the recommendation concurred on by a majority of the Panel, the final determination is that the Petition for Chronic Pain is approved.

helly Edgestr

Shelly Edgerton, Director Department of Licensing and Regulatory Affairs



STATE OF MICHIGAN DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS LANSING

SHELLY EDGERTON DIRECTOR

July 9, 2018

FINAL DETERMINATION OF THE DEPARTMENT

In accordance with the Michigan Medical Marihuana Act, Initiated Law 1 of 2008, MCL 333.26421, *et seq.* (MMMA), and the associated Michigan Administrative Rules, R 333.101 *et seq.*, a Petition was filed with the Department of Licensing and Regulatory Affairs (Department) to consider adding Colitis to the list of debilitating medical conditions under MCL 333.26423(b) and pursuant to R 333.131 and R 333.133.

The Medical Marihuana Review Panel (Panel) held a public hearing on April 27, 2018, to hear public comment on the Petition. In addition, public comment was accepted for five business days. In accordance with R 333.131(5), a majority of the Panel of those present at a meeting shall concur with the recommendation in order to be considered an official recommendation of the Panel.

On June 14, 2018, the Panel met to review and make a recommendation to the Department regarding whether the Petition should be approved or denied. After discussion, the Panel voted 4 to 3 to recommend that the Petition for Colitis be approved pursuant to MCL 333.26426(k). As required by MCL 333.26425(a), the official recommendation of the Panel now comes to the Department for final action. The Department shall approve or deny a Petition within 180 days of the submission of the Petition.

By the authority granted to the Department pursuant to the MMMA and associated Administrative Rules, and in consideration of the recommendation concurred on by a majority of the Panel, the final determination is that the Petition for Colitis is approved.

Shelly Edgerton, Director Department of Licensing and Regulatory Affairs



STATE OF MICHIGAN DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS LANSING

SHELLY EDGERTON DIRECTOR

July 9, 2018

FINAL DETERMINATION OF THE DEPARTMENT

In accordance with the Michigan Medical Marihuana Act, Initiated Law 1 of 2008, MCL 333.26421, *et seq.* (MMMA), and the associated Michigan Administrative Rules, R 333.101 *et seq.*, a Petition was filed with the Department of Licensing and Regulatory Affairs (Department) to consider adding Inflammatory Bowel Disease to the list of debilitating medical conditions under MCL 333.26423(b) and pursuant to R 333.131 and R 333.133.

The Medical Marihuana Review Panel (Panel) held a public hearing on April 27, 2018, to hear public comment on the Petition. In addition, public comment was accepted for five business days. In accordance with R 333.131(5), a majority of the Panel of those present at a meeting shall concur with the recommendation in order to be considered an official recommendation of the Panel.

On May 4, 2018, the Panel met to review and make a recommendation to the Department regarding whether the Petition should be approved or denied. After discussion, the Panel voted 6 to 0 to recommend that the Petition for Inflammatory Bowel Disease be approved pursuant to MCL 333.26426(k). As required by MCL 333.26425(a), the official recommendation of the Panel now comes to the Department for final action. The Department shall approve or deny a Petition within 180 days of the submission of the Petition.

By the authority granted to the Department pursuant to the MMMA and associated Administrative Rules, and in consideration of the recommendation concurred on by a majority of the Panel, the final determination is that the Petition for Inflammatory Bowel Disease is approved.

Shelly Edgert

Shelly Edgerton, Director Department of Licensing and Regulatory Affairs



STATE OF MICHIGAN DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS LANSING

SHELLY EDGERTON DIRECTOR

July 9, 2018

FINAL DETERMINATION OF THE DEPARTMENT

In accordance with the Michigan Medical Marihuana Act, Initiated Law 1 of 2008, MCL 333.26421, *et seq.* (MMMA), and the associated Michigan Administrative Rules, R 333.101 *et seq.*, a Petition was filed with the Department of Licensing and Regulatory Affairs (Department) to consider adding Obsessive Compulsive Disorder to the list of debilitating medical conditions under MCL 333.26423(b) and pursuant to R 333.131 and R 333.133.

The Medical Marihuana Review Panel (Panel) held a public hearing on April 27, 2018, to hear public comment on the Petition. In addition, public comment was accepted for five business days. In accordance with R 333.131(5), a majority of the Panel of those present at a meeting shall concur with the recommendation in order to be considered an official recommendation of the Panel.

On May 4, 2018, the Panel met to review and make a recommendation to the Department regarding whether the Petition should be approved or denied. After discussion, the Panel voted 4 to 2 to recommend that the Petition for Obsessive Compulsive Disorder be approved pursuant to MCL 333.26426(k). As required by MCL 333.26425(a), the official recommendation of the Panel now comes to the Department for final action. The Department shall approve or deny a Petition within 180 days of the submission of the Petition.

By the authority granted to the Department pursuant to the MMMA and associated Administrative Rules, and in consideration of the recommendation concurred on by a majority of the Panel, the final determination is that the Petition for Obsessive Compulsive Disorder is approved.

hell Edent

Shelly Edgerton, Director Department of Licensing and Regulatory Affairs



STATE OF MICHIGAN DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS LANSING

SHELLY EDGERTON DIRECTOR

July 9, 2018

FINAL DETERMINATION OF THE DEPARTMENT

In accordance with the Michigan Medical Marihuana Act, Initiated Law 1 of 2008, MCL 333.26421, *et seq.* (MMMA), and the associated Michigan Administrative Rules, R 333.101 *et seq.*, a Petition was filed with the Department of Licensing and Regulatory Affairs (Department) to consider adding Parkinson's Disease to the list of debilitating medical conditions under MCL 333.26423(b) and pursuant to R 333.131 and R 333.133.

The Medical Marihuana Review Panel (Panel) held a public hearing on April 27, 2018, to hear public comment on the Petition. In addition, public comment was accepted for five business days. In accordance with R 333.131(5), a majority of the Panel of those present at a meeting shall concur with the recommendation in order to be considered an official recommendation of the Panel.

On May 4, 2018, the Panel met to review and make a recommendation to the Department regarding whether the Petition should be approved or denied. After discussion, the Panel voted 6 to 0 to recommend that the Petition for Parkinson's Disease be approved pursuant to MCL 333.26426(k). As required by MCL 333.26425(a), the official recommendation of the Panel now comes to the Department for final action. The Department shall approve or deny a Petition within 180 days of the submission of the Petition.

By the authority granted to the Department pursuant to the MMMA and associated Administrative Rules, and in consideration of the recommendation concurred on by a majority of the Panel, the final determination is that the Petition for Parkinson's Disease is approved.

helly Ekart

Shelly Edgerton, Director Department of Licensing and Regulatory Affairs



STATE OF MICHIGAN DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS LANSING

SHELLY EDGERTON DIRECTOR

July 9, 2018

FINAL DETERMINATION OF THE DEPARTMENT

In accordance with the Michigan Medical Marihuana Act, Initiated Law 1 of 2008, MCL 333.26421, *et seq.* (MMMA), and the associated Michigan Administrative Rules, R 333.101 *et seq.*, a Petition was filed with the Department of Licensing and Regulatory Affairs (Department) to consider adding Rheumatoid Arthritis to the list of debilitating medical conditions under MCL 333.26423(b) and pursuant to R 333.131 and R 333.133.

The Medical Marihuana Review Panel (Panel) held a public hearing on April 27, 2018, to hear public comment on the Petition. In addition, public comment was accepted for five business days. In accordance with R 333.131(5), a majority of the Panel of those present at a meeting shall concur with the recommendation in order to be considered an official recommendation of the Panel.

On May 4, 2018, the Panel met to review and make a recommendation to the Department regarding whether the Petition should be approved or denied. After discussion, the Panel voted 5 to 1 to recommend that the Petition for Rheumatoid Arthritis be approved pursuant to MCL 333.26426(k). As required by MCL 333.26425(a), the official recommendation of the Panel now comes to the Department for final action. The Department shall approve or deny a Petition within 180 days of the submission of the Petition.

By the authority granted to the Department pursuant to the MMMA and associated Administrative Rules, and in consideration of the recommendation concurred on by a majority of the Panel, the final determination is that the Petition for Rheumatoid Arthritis is approved.

Shelly Edgertm

Shelly Edgerton, Director Department of Licensing and Regulatory Affairs



STATE OF MICHIGAN DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS LANSING

SHELLY EDGERTON DIRECTOR

July 9, 2018

FINAL DETERMINATION OF THE DEPARTMENT

In accordance with the Michigan Medical Marihuana Act, Initiated Law 1 of 2008, MCL 333.26421, *et seq.* (MMMA), and the associated Michigan Administrative Rules, R 333.101 *et seq.*, a Petition was filed with the Department of Licensing and Regulatory Affairs (Department) to consider adding Spinal Cord Injury to the list of debilitating medical conditions under MCL 333.26423(b) and pursuant to R 333.131 and R 333.133.

The Medical Marihuana Review Panel (Panel) held a public hearing on April 27, 2018, to hear public comment on the Petition. In addition, public comment was accepted for five business days. In accordance with R 333.131(5), a majority of the Panel of those present at a meeting shall concur with the recommendation in order to be considered an official recommendation of the Panel.

On May 4, 2018, the Panel met to review and make a recommendation to the Department regarding whether the Petition should be approved or denied. After discussion, the Panel voted 4 to 2 to recommend that the Petition for Spinal Cord Injury be approved pursuant to MCL 333.26426(k). As required by MCL 333.26425(a), the official recommendation of the Panel now comes to the Department for final action. The Department shall approve or deny a Petition within 180 days of the submission of the Petition.

By the authority granted to the Department pursuant to the MMMA and associated Administrative Rules, and in consideration of the recommendation concurred on by a majority of the Panel, the final determination is that the Petition for Spinal Cord Injury is approved.

heller Edgest

Shelly Edgerton, Director Department of Licensing and Regulatory Affairs



STATE OF MICHIGAN DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS LANSING

SHELLY EDGERTON DIRECTOR

July 9, 2018

FINAL DETERMINATION OF THE DEPARTMENT

In accordance with the Michigan Medical Marihuana Act, Initiated Law 1 of 2008, MCL 333.26421, *et seq.* (MMMA), and the associated Michigan Administrative Rules, R 333.101 *et seq.*, a Petition was filed with the Department of Licensing and Regulatory Affairs (Department) to consider adding Tourette's Syndrome to the list of debilitating medical conditions under MCL 333.26423(b) and pursuant to R 333.131 and R 333.133.

The Medical Marihuana Review Panel (Panel) held a public hearing on April 27, 2018, to hear public comment on the Petition. In addition, public comment was accepted for five business days. In accordance with R 333.131(5), a majority of the Panel of those present at a meeting shall concur with the recommendation in order to be considered an official recommendation of the Panel.

On May 4, 2018, the Panel met to review and make a recommendation to the Department regarding whether the Petition should be approved or denied. After discussion, the Panel voted 6 to 0 to recommend that the Petition for Tourette's Syndrome be approved pursuant to MCL 333.26426(k). As required by MCL 333.26425(a), the official recommendation of the Panel now comes to the Department for final action. The Department shall approve or deny a Petition within 180 days of the submission of the Petition.

By the authority granted to the Department pursuant to the MMMA and associated Administrative Rules, and in consideration of the recommendation concurred on by a majority of the Panel, the final determination is that the Petition for Tourette's Syndrome is approved.

elly Edersh

Shelly Edgerton / Director Department of Licensing and Regulatory Affairs



STATE OF MICHIGAN DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS LANSING

SHELLY EDGERTON DIRECTOR

July 9, 2018

FINAL DETERMINATION OF THE DEPARTMENT

In accordance with the Michigan Medical Marihuana Act, Initiated Law 1 of 2008, MCL 333.26421, *et seq.* (MMMA), and the associated Michigan Administrative Rules, R 333.101 *et seq.*, a Petition was filed with the Department of Licensing and Regulatory Affairs (Department) to consider adding Ulcerative Colitis to the list of debilitating medical conditions under MCL 333.26423(b) and pursuant to R 333.131 and R 333.133.

The Medical Marihuana Review Panel (Panel) held a public hearing on April 27, 2018, to hear public comment on the Petition. In addition, public comment was accepted for five business days. In accordance with R 333.131(5), a majority of the Panel of those present at a meeting shall concur with the recommendation in order to be considered an official recommendation of the Panel.

On May 4, 2018, the Panel met to review and make a recommendation to the Department regarding whether the Petition should be approved or denied. After discussion, the Panel voted 6 to 0 to recommend that the Petition for Ulcerative Colitis be approved pursuant to MCL 333.26426(k). As required by MCL 333.26425(a), the official recommendation of the Panel now comes to the Department for final action. The Department shall approve or deny a Petition within 180 days of the submission of the Petition.

By the authority granted to the Department pursuant to the MMMA and associated Administrative Rules, and in consideration of the recommendation concurred on by a majority of the Panel, the final determination is that the Petition for Ulcerative Colitis is approved.

helle Edmite

Shelly Edgerton, Director Department of Licensing and Regulatory Affairs